Medicines loses Angiomax patent fight at Federal Circuit
This article was originally published in Scrip
Executive Summary
The US Court of Appeals for the Federal Circuit on 2 July declared that two patents on The Medicines Company's top-selling anticoagulant Angiomax (bivalirudin) were invalid – ruling in favor of Hospira and opening the door for the company and others to market generic copycats in the US.